Exagen (NASDAQ:XGN) Stock Gets Downgrade from Wall Street Zen

Exagen (NASDAQ:XGN – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

XGN has been the subject of several other research reports. BTIG Research reaffirmed a “buy” rating and issued a $9.00 target price on shares of Exagen in a research report on Wednesday, November 11th. TD Cowen lifted their price target on Exagen from $10.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Exagen in a research report on Wednesday, November 4th. Canaccord Genuity Group reduced their price objective on Exagen from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, November 11th. Finally, B. Riley Financial initiated coverage on Exagen in a research note on Friday, September 11th. They issued a “buy” rating and a $12.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.88.

Read Our Latest Stock Report on Exagen

Exagen Stock Performance

Shares of XGN opened at $4.13 on Friday. The firm’s 50 day moving average is $7.71 and its 200-day moving average is $5.13. The stock has a market capitalization of $105.36 million, a P/E ratio of -5.51 and a beta of 2.25. The company has a debt-to-equity ratio of 1.73, a current ratio of 3.46 and a quick ratio of 3.46. Exagen has a 12-month low of $2.59 and a 12-month high of $9.28.

Exagen (NASDAQ:XGN – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The company had revenue of $18.42 million for the quarter, compared to the consensus estimate of $18.34 million. Exagen had a negative return on equity of 125.60% and a negative net margin of 25.14%. Equities research analysts anticipate that Exagen will post -0.71 EPS for the current fiscal year.

Insider Activity at Exagen

In other news, major shareholder Jorey Chernett sold 58,068 shares of the firm’s stock in a transaction on Friday, November 13th. The shares were sold at an average price of $4.08, for a total transaction of $236,917.44. Following the transaction, the insider owned 2,529,436 shares in the company, valued at approximately $10,320,098.88. This trade represents a 2.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John Aballi sold 34,294 shares of Exagen stock in a transaction on Friday, October 16th. The shares were sold at an average price of $7.87, for a total transaction of $269,893.78. Following the completion of the sale, the chief executive officer directly owned 805,540 shares of the company’s stock, valued at approximately $6,339,599.80. The trade was a 4.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders acquired 100,900 shares of company stock valued at $568,660 and sold 213,063 shares valued at $1,084,856. Insiders own 10.40% of the company’s stock.

Hedge Funds Weigh In On Exagen

Several hedge funds have recently bought and sold shares of XGN. Corient Private Wealth LP acquired a new stake in Exagen in the 2nd quarter worth approximately $52,000. Penbrook Management LLC bought a new stake in Exagen during the third quarter worth approximately $92,000. Calamos Advisors LLC acquired a new position in Exagen during the third quarter valued at approximately $94,000. Bank of New York Mellon Corp acquired a new position in Exagen during the second quarter valued at approximately $97,000. Finally, Dimensional Fund Advisors LP grew its holdings in Exagen by 137.4% during the first quarter. Dimensional Fund Advisors LP now owns 62,571 shares of the company’s stock valued at $188,000 after purchasing an additional 36,213 shares during the last quarter. 75.25% of the stock is owned by institutional investors and hedge funds.

Key Exagen News

Here’s some of the latest news about XGN:

Exagen Company Profile

(Get Free Report)

Exagen Inc. is a diagnostics company focused on testing for autoimmune and rheumatic diseases. It develops and provides blood tests intended to help physicians assess and monitor conditions such as systemic lupus erythematosus and other connective tissue diseases. The company’s AVISE test portfolio includes diagnostic and monitoring tests that use proprietary biomarkers to support clinical evaluation. Its offerings are designed to provide information that may help clinicians distinguish among autoimmune conditions and guide patient care.

Featured Articles

Analyst Recommendations for Exagen (NASDAQ:XGN)

Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.